RxDoctor Payments Data

Mary Brooks

Nurse Practitioner · Roanoke, VANPI 1336487404

Payments from drug & device makers

$2,549in general payments, 2019–2025

Across 125 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$595
  • Hollister Incorporated$283
  • Gilead$251
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$204
  • Takeda Pharmaceuticals U.S.A., Inc.$153
  • Aimmune Therapeutics, Inc.$151
  • plus $912 from 19 others

What the payments were for

  • Food & beverage$2,549100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,549 in reported general payments places this provider in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Medicare billing

Part B allowed, 2024
$82,114
Medicare patients
553
Services billed
876

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide26$19,671
Mesalamine23$13,721
Famotidine286$4,876
Budesonide EcBudesonide13$4,442
Ursodiol13$3,706
Dicyclomine Hcl116$2,601
Pantoprazole Sodium284$2,541
Colestipol Hcl28$1,730
Omeprazole145$1,604
Ondansetron OdtOndansetron33$1,131
Ondansetron Hcl44$897
Sucralfate20$755
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine23$622
Esomeprazole Magnesium16$549
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg23$524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$595$19,67126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →